Investigating how cancer cells produce unique proteins in non-small cell lung cancer
Official title: Alternate splicing as a source of shared neoantigens in a non-small cell lung cancer
Funded at University of Connecticut Sch of Med/dnt · NIH-10884212 · Data updated 2026-11-12
This study is looking at ways to make current treatments for non-small cell lung cancer work better by creating special vaccines that help your immune system recognize and fight the cancer cells more effectively, especially for those who haven't had success with standard therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 5F30CA278494-02 |
| Project ID | NIH-10884212 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are seeking new treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on non-small cell lung cancer (NSCLC), a leading cause of cancer deaths. It aims to enhance the effectiveness of existing immunotherapies by developing cancer vaccines that target unique proteins, known as neoantigens, produced by cancer cells through a process called alternative splicing. By using advanced RNA sequencing techniques, the researchers will identify these neoantigens and assess their potential to stimulate the immune system, specifically CD8+ T cells, to attack tumor cells more effectively. The goal is to improve treatment responses for patients who currently do not benefit from standard therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer vaccines that improve survival rates for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promise in targeting neoantigens for cancer treatment, indicating that this approach could be a significant advancement in cancer immunotherapy.
Where this research is happening
-
University of Connecticut Sch of Med/dnt
Farmington, United States Active
Researchers
- Principal investigator: Englander, Ryan — University of Connecticut Sch of Med/dnt
- Study coordinator: Englander, Ryan
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.